Differences in circulating angiogenic biomarkers as prognosticator for outcome in bevacizumab-treated nonsquamous non-small cell lung cancer (NSCLC) patients.

Marta Batus,Ravi Pithadia,John C. Kubasiak,Cristina Fhied,Zahraa Ibrahem,Shruthi Melinamani,Ibdihaj Fughhi,Wen-Rong Lie,Sanjib Basu,Mary J. Fidler,Philip Bonomi,Jeffrey A. Borgia

Differences in circulating angiogenic biomarkers as prognosticator for outcome in bevacizumab-treated nonsquamous non-small cell lung cancer (NSCLC) patients.

2014

Marta Batus
Ravi Pithadia
John C. Kubasiak
Cristina Fhied
Zahraa Ibrahem
Shruthi Melinamani
Ibdihaj Fughhi
Wen-Rong Lie
Sanjib Basu
Mary J. Fidler
Philip Bonomi
Jeffrey A. Borgia

11037 Background: Trials evaluating role of bevacizumab in patients with advanced NSCLC have shown only modest impact in outcomes. The objective of this study was to evaluate predictive value of pa...

Keywords:

non-small cell lung cancer (NSCLC)
Bevacizumab
Pathology
Biomarker (medicine)
Medicine
Oncology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations